Resources
9 Results (showing 1 - 9)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/2/2021 (updated 4/4/2024)
This session will walk through the strategic plan template provided by JBS International in the Grantee Onboarding Packet for HRSA RCORP-Planning Grantees. During this workshop style webinar, facilitators will walk grantees through the template section by section, discussing the required elements and providing examples of each section. Grantees will learn how to use their data to determine problem statements, goals, objectives, and outcomes for their strategic plan as well as how to include metrics to successfully track their progress.
Posted 10/26/2021 (updated 4/3/2024)
Posted 9/14/2020 (updated 3/29/2024)
The RCORP-TA Policy Academy Town Hall took place on September 1, 2020.
Please find the presentation and recording posted here.
Posted 12/30/2019 (updated 3/28/2024)
Basic overview of substance use as a complex but treatable disease that affects brain function.
Posted 6/15/2020 (updated 3/28/2024)
The Opioid Use Disorder, Pregnant Women and Neonatal Abstinence Syndrome (NAS): Addressing the Challenges (Part II) webinar took place on June 9, 2020.
Posted 6/15/2020 (updated 3/28/2024)
Trends in HIV Prevention and Care Webinar took place on June 4, 2020. Click for the presentation and recording.
Posted 8/12/2020 (updated 3/28/2024)
The Recognizing and Addressing Rural Homeless in Opioid Use Disorder (OUD) Programs webinar took place Tuesday, August 04, 2020. The presentation and video recording are included.
Posted 12/15/2023 (updated 3/28/2024)
The Opioid-Overdose Reduction Continuum of Care Approach is a guide for policymakers for implementing evidence-based strategies that address opioid overdose.
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.